Search for other papers by Nicolás Crisosto in
Google Scholar
PubMed
Search for other papers by Bárbara Echiburú in
Google Scholar
PubMed
Search for other papers by Manuel Maliqueo in
Google Scholar
PubMed
Search for other papers by Marta Luchsinger in
Google Scholar
PubMed
Search for other papers by Pedro Rojas in
Google Scholar
PubMed
Search for other papers by Sergio Recabarren in
Google Scholar
PubMed
Search for other papers by Teresa Sir-Petermann in
Google Scholar
PubMed
.038 1.23 (0.87–1.62) 1.38 (1.13–1.87) 0.109 17 OH progesterone (ng/mL) 0.61 (0.47–1.2) 0.68 (0.43–0.88) 0.801 0.69 (0.5–1.19) 0.66 (0.55–0.95) 0.976 1.33 (0.99–2.04) 1.56 (1.33–2.48) 0.085 FAI 0.7 (0.3–1.1) 1.0 (0
West Cancer Center, Memphis, Tennessee, USA
Search for other papers by Michael Ulm in
Google Scholar
PubMed
Search for other papers by Arvind V Ramesh in
Google Scholar
PubMed
Search for other papers by Keely M McNamara in
Google Scholar
PubMed
Search for other papers by Suriyan Ponnusamy in
Google Scholar
PubMed
Search for other papers by Hironobu Sasano in
Google Scholar
PubMed
West Cancer Center, Memphis, Tennessee, USA
Search for other papers by Ramesh Narayanan in
Google Scholar
PubMed
the AR being activated by other hormones such as progesterone, corticosteroids, estradiol and others. 2. AR amplification and mutations. The AR copy numbers increase leading to an increase in the expression of AR that will become hyperactive and will
Search for other papers by Lina S Silva-Bermudez in
Google Scholar
PubMed
Search for other papers by Freddy J K Toloza in
Google Scholar
PubMed
Search for other papers by Maria C Perez-Matos in
Google Scholar
PubMed
Search for other papers by Russell J de Souza in
Google Scholar
PubMed
Search for other papers by Laura Banfield in
Google Scholar
PubMed
Search for other papers by Andrea Vargas-Villanueva in
Google Scholar
PubMed
Search for other papers by Carlos O Mendivil in
Google Scholar
PubMed
related to testosterone and may have been undesirable androgenic effects ( 2 ). Newer progestins derived from progesterone or spironolactone (cyproterone, chlormadinone, nomegestrol, drospirenone) are expected to result in a more favorable metabolic
Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK
Search for other papers by M Guftar Shaikh in
Google Scholar
PubMed
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Search for other papers by Timothy G Barrett in
Google Scholar
PubMed
Search for other papers by Nicola Bridges in
Google Scholar
PubMed
Search for other papers by Robin Chung in
Google Scholar
PubMed
Centre for Endocrinology, William Harvey Research Institute, Barts and The London Medical School, Queen Mary University of London, London, UK
Search for other papers by Evelien F Gevers in
Google Scholar
PubMed
Department of Endocrinology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK
Search for other papers by Anthony P Goldstone in
Google Scholar
PubMed
Search for other papers by Anthony Holland in
Google Scholar
PubMed
Search for other papers by Shankar Kanumakala in
Google Scholar
PubMed
Search for other papers by Ruth Krone in
Google Scholar
PubMed
Department of Paediatric Endocrinology, Makarios Children's Hospital, Nicosia, Cyprus
Search for other papers by Andreas Kyriakou in
Google Scholar
PubMed
Sussex Community NHS Trust, Brighton, UK
Search for other papers by E Anne Livesey in
Google Scholar
PubMed
Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK
Search for other papers by Angela K Lucas-Herald in
Google Scholar
PubMed
Search for other papers by Christina Meade in
Google Scholar
PubMed
Search for other papers by Susan Passmore in
Google Scholar
PubMed
The University of Dublin, Trinity College Dublin, Dublin, Republic of Ireland
Search for other papers by Edna Roche in
Google Scholar
PubMed
Search for other papers by Chris Smith in
Google Scholar
PubMed
Search for other papers by Sarita Soni in
Google Scholar
PubMed
bleeds are achieved, a progesterone should be added as per BSPED guidelines. In adults, either 17β-oestradiol patches (e.g. Evorel © ) or topical oestrogen gel (Sandrena © ) are preferred, especially if there is severe obesity or hypertension. Oral
Search for other papers by Anastasia P Athanasoulia-Kaspar in
Google Scholar
PubMed
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany
Search for other papers by Matthias K Auer in
Google Scholar
PubMed
Search for other papers by Günter K Stalla in
Google Scholar
PubMed
Search for other papers by Mira Jakovcevski in
Google Scholar
PubMed
) and with estrogen/progesterone replacement in women or in case of past hysterectomy with estradiol only. GHD was treated with recombinant human GH. One hundred six controls were selected from a large control group previously recruited for the scope
Search for other papers by Shuang Ye in
Google Scholar
PubMed
Search for other papers by Yuanyuan Xu in
Google Scholar
PubMed
Search for other papers by Jiehao Li in
Google Scholar
PubMed
Search for other papers by Shuhui Zheng in
Google Scholar
PubMed
Search for other papers by Peng Sun in
Google Scholar
PubMed
Search for other papers by Tinghuai Wang in
Google Scholar
PubMed
Background Triple-negative breast cancer (TNBC) is negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (HER-2), and accounts for 15–20% of all breast cancers ( 1 ). Due to this lack of the
Department of Pediatrics, St. Anna Kinderspital, Medical University of Vienna, Vienna, Austria
Search for other papers by Stefan Riedl in
Google Scholar
PubMed
Search for other papers by Friedrich-Wilhelm Röhl in
Google Scholar
PubMed
Search for other papers by Walter Bonfig in
Google Scholar
PubMed
Search for other papers by Jürgen Brämswig in
Google Scholar
PubMed
Search for other papers by Annette Richter-Unruh in
Google Scholar
PubMed
Search for other papers by Susanne Fricke-Otto in
Google Scholar
PubMed
Search for other papers by Markus Bettendorf in
Google Scholar
PubMed
Search for other papers by Felix Riepe in
Google Scholar
PubMed
Search for other papers by Gernot Kriegshäuser in
Google Scholar
PubMed
Search for other papers by Eckhard Schönau in
Google Scholar
PubMed
Search for other papers by Gertrud Even in
Google Scholar
PubMed
Search for other papers by Berthold Hauffa in
Google Scholar
PubMed
Search for other papers by Helmuth-Günther Dörr in
Google Scholar
PubMed
Search for other papers by Reinhard W Holl in
Google Scholar
PubMed
Search for other papers by Klaus Mohnike in
Google Scholar
PubMed
Search for other papers by the AQUAPE CAH Study Group in
Google Scholar
PubMed
detection of common CYP21A2 mutations in dried blood spots from newborns with elevated 17-OH progesterone . Clinica Chimica Acta 2012 414 211 – 214 . ( https://doi.org/10.1016/j.cca.2012.09.013 ) 10.1016/j.cca.2012.09.013
Search for other papers by Jonneke J Hollanders in
Google Scholar
PubMed
Search for other papers by Bibian van der Voorn in
Google Scholar
PubMed
Search for other papers by Noera Kieviet in
Google Scholar
PubMed
Search for other papers by Koert M Dolman in
Google Scholar
PubMed
Search for other papers by Yolanda B de Rijke in
Google Scholar
PubMed
Search for other papers by Erica L T van den Akker in
Google Scholar
PubMed
Search for other papers by Joost Rotteveel in
Google Scholar
PubMed
Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands
Search for other papers by Adriaan Honig in
Google Scholar
PubMed
Search for other papers by Martijn J J Finken in
Google Scholar
PubMed
and progesterone concentrations between women with and without term labor. A comparison . Journal of Reproductive Medicine 1996 41 80 – 86 . 11 Fencl MM Koos B Tulchinsky D. Origin of corticosteroids in amniotic fluid . Journal
Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
Search for other papers by Hanne Mumm in
Google Scholar
PubMed
Search for other papers by Jens Juul Holst in
Google Scholar
PubMed
Search for other papers by Marianne Andersen in
Google Scholar
PubMed
free testosterone ( 14 ). OCP may increase body weight ( 15 ) and insulin resistance ( 14 , 16 ), which could be associated with decreased GLP-1 levels. In contrast, animal studies suggested that estradiol and progesterone treatment could increase the
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Milène Tetsi Nomigni in
Google Scholar
PubMed
Search for other papers by Sophie Ouzounian in
Google Scholar
PubMed
Search for other papers by Alice Benoit in
Google Scholar
PubMed
Search for other papers by Jacqueline Vadrot in
Google Scholar
PubMed
Search for other papers by Frédérique Tissier in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Sylvie Renouf in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Hervé Lefebvre in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Sophie Christin-Maitre in
Google Scholar
PubMed
INSERM, University of Rouen, Department of Endocrinology, Departments of Endocrinology, Pathology, Department of Pathology, Department of Endocrinology, INSERM, U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Institute for Research and Innovation in Biomedicine, Mont‐Saint‐Aignan, France
Search for other papers by Estelle Louiset in
Google Scholar
PubMed
/l) 24.3 2–7 Baseline 17-OH progesterone (nmol/l) 3.2 1–5 17-OHP post ACTH (nmol/l) 7.6 <25 DHEAS (μmol/l) 1.2 1.5–7 Cortisol 0800 h (nmol/l) 175 220–610 Cortisol 60′ post ACTH (nmol/l) 345 >540